Comment
doi: 10.1016/S2352-3018(21)00106-5.
Two-drug HIV regimens: more data still needed
Affiliations
- PMID: 34358493
- DOI: 10.1016/S2352-3018(21)00106-5
Item in Clipboard
Comment
Two-drug HIV regimens: more data still needed
Lancet HIV.
2021 Aug.
No abstract available
Comment on
-
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.Lancet HIV. 2021 Aug;8(8):e463-e473. doi: 10.1016/S2352-3018(21)00100-4. Lancet HIV. 2021. PMID: 34358497 Clinical Trial.
Similar articles
-
[Adherence to the antiretroviral treatment].Rev Clin Esp. 2003 Jun;203(6):299-302. doi: 10.1157/13047623. Rev Clin Esp. 2003. PMID: 12783718 Review. Spanish. No abstract available.
-
Better salvage therapy for HIV-1 infection still needed.Lancet. 1999 May 29;353(9167):1857. doi: 10.1016/S0140-6736(99)00094-X. Lancet. 1999. PMID: 10359423 No abstract available.
-
Transmitted minority drug-resistant HIV variants: a new epidemic?PLoS Med. 2008 Jul 29;5(7):e164. doi: 10.1371/journal.pmed.0050164. PLoS Med. 2008. PMID: 18666826 Free PMC article.
-
Antiretroviral Drug Recommendations for HIV Treatment and Prevention-Reply.JAMA. 2021 Mar 2;325(9):889-890. doi: 10.1001/jama.2020.25990. JAMA. 2021. PMID: 33651088 No abstract available.
-
The Impact of HIV-1 Drug Escape on the Global Treatment Landscape.Cell Host Microbe. 2019 Jul 10;26(1):48-60. doi: 10.1016/j.chom.2019.06.010. Cell Host Microbe. 2019. PMID: 31295424 Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
